Amneal recently announced the appointment of Sandeep Raktate as its President-Operations, India & Ireland. The company also informed that Raktate and his team will be focused on advancing the company’s manufacturing of top quality, complex medicines.  Raktate has around 29 years of rich experience in pharma and bio-pharma sector. His experience spans across biotechnology, pharmacy, management, validation, and GMP. He is currently focussed on Operations Management and project management. In his last stint, he served as EVP, Head-International Operations and Central Manufacturing at Ci ..read more

Dr. Reddy’s Laboratories announced the roll-out of its condition management programme DailyBloom IBS, India’s first integrated care plan for Irritable Bowel Syndrome (IBS). The programme is enabled by a mobile application developed in-house. A press statement informed that DailyBloom IBS focuses on a comprehensive care plan that includes diet management, psychological and physical wellness support for patients with IBS. Dr. Reddy’s has launched the programme on ‘World IBS Day’, a day that aims to increase awareness of the IBS condition, discuss misconceptions, challenges and even stigma attac ..read more

Given the complex pathophysiology of Alzheimer’s disease (AD), developing disease modifying therapies (DMTs) that target different aspects of AD pathology is critical. American clinical-stage biopharmaceutical company Alzheon has recently presented promising interim results from its Phase II Biomarker Trial (NCT04693520) of its oral, brain-penetrant, amyloid-oligomer inhibitor ALZ-801 (valiltramiprosate). Against this backdrop, ALZ-801 has the potential to be the first oral Aβ-targeting therapy to be approved in the US and EU in early AD, says GlobalData. Erela Dana, Director of Neurolog ..read more

Given the complex pathophysiology of Alzheimer’s disease (AD), developing disease modifying therapies (DMTs) that target different aspects of AD pathology is critical. American clinical-stage biopharmaceutical company Alzheon has recently presented promising interim results from its Phase II Biomarker Trial (NCT04693520) of its oral, brain-penetrant, amyloid-oligomer inhibitor ALZ-801 (valiltramiprosate). Against this backdrop, ALZ-801 has the potential to be the first oral Aβ-targeting therapy to be approved in the US and EU in early AD, says GlobalData. Erela Dana, Director of Neurolog ..read more

Akums Drugs & Pharmaceuticals recently launched its 20th Anniversary Campaign, “BHAROSA – Two Decades of Trust, Going Strong.” A statement from the company informed, “Through the Bharosa Campaign, Akums seeks to raise awareness about its steadfast commitment to sustainability and innovation, both of which align with the company’s long-term vision and core values.” It also informed, “With a market share of 9.3 per cent of the total addressable Indian domestic CDMO market by value and 8.8 per cent in the IPM market by volume in FY23, Akums has consistently demonstrated its leadership in the ..read more

Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes. Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commerci ..read more

ENTOD Pharmaceuticals received approval from CDSCO for PresVu, a treatment for presbyopia, by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). PresVu is a eye drop in India designed to alleviate the need for reading glasses among individuals grappling with presbyopia. Presbyopia, characterised by blurred near vision due to the decreased flexibility of the eye’s natural lens, primarily impacts individuals aged 40 and above. PresVu offers swift relief and temporary correction of vision problems associated with presbyopia. PresVu eye drops adjust rap ..read more

Merck recently announced the appointment of Dhananjay Singh as the Managing Director of Merck Life Science in India, in addition to his current position as Head of Science & Lab Solutions Commercial, India. Effective April 1, 2024, Dhananjay Singh has taken over from Sreenath NS, who is retiring after 36 years of illustrious service with Merck in India. “As an expert with 26 years with Merck, Dhananjay has been instrumental in shaping the Science and Lab Solutions Commercial business in India and is exemplary in his commitment to advancing scientific progress in partnership with our custo ..read more

Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5 billion increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD), with more than $2 billion forged in Q1 2024 alone, reveals GlobalData. MASH, previously known as nonalcoholic steatohepatitis (NASH), is a disease characteriSed by liver inflammation and damage caused by the accumulation of fat. Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), a small molecule THRB agonist, was the fi ..read more

Panelists in this video: + Mr SG Belapure, Sr. Technical Advisor, IPA (Moderator) + Dr Viranchi Shah, National President, Indian Drug Manufacturers Association (IDMA) + Mr Vijay Charlu, President, Corona Remedies + Mr Rajiv Gandhi, CEO & MD, Hester Biosciences + Mr Sanjay Sharma, Sr VP & Head-Manufacturing Science and Technology, Zydus Group Key Highlights: [1] An entrepreneurial mindset, conducive business climate and presence of good resources have made Ahmedabad a leading pharma hub. [2] Gujarat is the pharmacy of India. It produces one third of the drugs produced in India. It exp ..read more